Childhood & Juvenile Absence Epilepsy
Absence epilepsy syndromes are among the most recognizable and well-characterized forms of genetic generalized epilepsy. Childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) represent the two age-defined syndromes within this group, both featuring absence seizures as a core feature but differing in age of onset, seizure frequency, associated seizure types, and long-term prognosis. The ILAE 2022 classification formally defines CAE and JAE as distinct idiopathic generalized epilepsy syndromes, each with specific diagnostic criteria. Absence seizures are characterized by abrupt-onset, brief episodes of impaired awareness with generalized 3 Hz spike-and-wave discharges on EEG, provokable by hyperventilation. Accurate syndromic diagnosis is essential because treatment choices and prognostic counseling differ significantly between CAE, JAE, and other generalized epilepsies.
Bottom Line
- Childhood absence epilepsy (CAE): Onset between ages 4 and 10 years; very frequent typical absence seizures (dozens per day); characteristic 3 Hz generalized spike-and-wave discharges; normal development; remission in 60–70% by adolescence
- Juvenile absence epilepsy (JAE): Onset between ages 9 and 13 years; less frequent absences than CAE; higher likelihood of generalized tonic-clonic seizures (80%) and occasional myoclonic seizures; typically requires lifelong treatment
- Diagnosis: EEG with hyperventilation is the most important diagnostic tool; 3 Hz generalized spike-and-wave discharges during an absence seizure are virtually pathognomonic; hyperventilation provokes seizures in >90% of untreated patients with CAE
- Treatment: Ethosuximide is first-line for CAE without generalized tonic-clonic seizures (SANAD II); valproate and lamotrigine are alternatives; valproate is preferred when GTC seizures coexist; lamotrigine is less effective for absence seizure control but better tolerated
- Drugs to avoid: Carbamazepine, oxcarbazepine, phenytoin, and vigabatrin may worsen absence seizures
Childhood Absence Epilepsy
Epidemiology and Genetics
CAE accounts for approximately 10–17% of all childhood epilepsies, with an annual incidence of 6–8 per 100,000 in children under 15 years of age. The peak onset is between 5 and 7 years, with a slight female predominance. CAE is considered a genetic generalized epilepsy with complex, polygenic inheritance. Multiple susceptibility loci have been identified, including variants in genes encoding GABAA receptor subunits (GABRG2, GABRA1, GABRB3), calcium channel subunits (CACNA1H), and glucose transporter type 1 (SLC2A1). However, no single gene accounts for most cases, and the genetic architecture remains incompletely understood. A family history of epilepsy is present in 15–40% of patients, typically involving other forms of genetic generalized epilepsy.
Clinical Features
The hallmark of CAE is the typical absence seizure:
- Onset and offset: Abrupt interruption of ongoing activity with a blank stare and unresponsiveness; equally abrupt return to baseline without postictal confusion
- Duration: Typically 4–30 seconds (average 10–15 seconds)
- Frequency: Often dozens to hundreds per day; may go unrecognized by parents and teachers for months
- Subtle motor accompaniments: Eyelid fluttering (3 Hz), rhythmic head nodding, mild oral automatisms (lip smacking), or subtle limb myoclonus; these are common and do not reclassify the seizure type
- Awareness: Fully impaired during the seizure; the child has no recollection of the episode
- Provocation: Hyperventilation for 3–5 minutes provokes absence seizures in >90% of untreated patients—this is the single most reliable provocative maneuver
Recognizing Absence Seizures in the Clinic
- Ask the child to hyperventilate for 3–5 minutes while counting or blowing on a pinwheel; observe for staring, eye flutter, and interruption of counting
- Parents often describe the child as "daydreaming," "spacing out," or "not paying attention in school"—distinguish from inattention by the abrupt onset/offset and brief, stereotyped nature of the episodes
- Absence seizures are NOT preceded by an aura and do NOT have postictal confusion—if either is present, consider focal seizures with impaired awareness
- Video-EEG during hyperventilation can simultaneously demonstrate the clinical seizure and the associated 3 Hz spike-and-wave discharge
EEG Features
| EEG Feature | Childhood Absence Epilepsy | Juvenile Absence Epilepsy |
|---|---|---|
| Ictal discharge | Regular 3 Hz (range 2.5–4 Hz) generalized spike-and-wave | Regular 3–5.5 Hz generalized spike-and-wave or polyspike-and-wave |
| Discharge duration | Typically 4–20 seconds; longer discharges more common than in JAE | Often briefer; may not be clinically apparent if <3 seconds |
| Interictal pattern | Regular 2.5–4 Hz generalized spike-wave bursts | Regular 3–5.5 Hz generalized spike-wave; occasional polyspikes |
| Background | Normal | Normal |
| Hyperventilation activation | Highly effective (>90%) | Effective but less reliably than in CAE |
| Photosensitivity | Uncommon (~10%) | More common (~15–25%) |
| Frequency slowing | May slow from 3 Hz to 2.5 Hz at the end of a prolonged discharge | Less frequency variation during discharges |
ILAE 2022 Diagnostic Criteria for CAE
The ILAE 2022 classification defines CAE with the following mandatory and exclusion criteria:
- Mandatory: Onset between ages 4 and 10 years; frequent typical absence seizures (usually daily); 2.5–4 Hz generalized spike-and-wave discharges; normal development and neurologic examination at onset
- Exclusion criteria: Myoclonic seizures; eyelid myoclonia; tonic, atonic, or focal seizures; intellectual disability; generalized tonic-clonic seizures at onset (GTC may develop later in a minority)
- Alert: If an individual has generalized seizures with generalized spike-wave in the 2.5–5.5 Hz range but does not meet specific criteria for CAE, JAE, or JME, they should be classified as having genetic generalized epilepsy (not otherwise specified)
Juvenile Absence Epilepsy
Clinical Features
JAE is distinguished from CAE by later onset, lower absence seizure frequency, and a higher prevalence of generalized tonic-clonic seizures:
| Feature | CAE | JAE |
|---|---|---|
| Age of onset | 4–10 years (peak 5–7) | 9–13 years (peak 10–12) |
| Absence frequency | Very frequent (dozens/day) | Less frequent (several per week to few per day) |
| GTC seizures | ~15–30% (usually in adolescence) | ~80% (often the presenting seizure type) |
| Myoclonic seizures | Not part of the syndrome | Occasional (~15–25%); if prominent, consider JME |
| Gender predilection | Slight female predominance | Equal or slight female predominance |
| EEG spike-wave frequency | 2.5–4 Hz (classic 3 Hz) | 3–5.5 Hz; polyspikes more common |
| Remission | 60–70% by adolescence | Uncommon; typically requires lifelong treatment |
| Classification | Self-limited (ILAE 2022) | Not self-limited (ILAE 2022) |
Overlap With Other Idiopathic Generalized Epilepsies
JAE exists on a spectrum with juvenile myoclonic epilepsy (JME) and epilepsy with generalized tonic-clonic seizures alone. Distinguishing these syndromes is clinically important because treatment and prognosis differ. The presence of morning myoclonic jerks (particularly upon awakening) favors JME. Both JAE and JME may present with generalized tonic-clonic seizures as the initial recognized seizure type, and a careful history for prior unrecognized absences or myoclonic jerks is essential.
Atypical Absence Seizures
Atypical absence seizures differ from typical absences in several important respects and are associated with more severe epilepsy syndromes, particularly Lennox-Gastaut syndrome:
- Onset and offset: More gradual than typical absences; the transition between seizure and non-seizure states is less distinct
- Duration: Often longer than typical absences
- Motor features: More prominent changes in tone (including head drops or subtle tonic stiffening); eyelid myoclonia may be more prominent
- EEG: Slow spike-and-wave discharges (<2.5 Hz), often with irregular morphology and poorly organized background
- Clinical context: Occur in children with cognitive impairment and drug-resistant epilepsy; seen in ~60% of patients with Lennox-Gastaut syndrome
- Prognosis: Not self-limited; typically part of a developmental and epileptic encephalopathy
Treatment
First-Line Pharmacotherapy
The landmark SANAD (Standard and New Antiepileptic Drugs) trials and subsequent evidence guide treatment selection for absence epilepsy:
| Medication | Mechanism | Efficacy in Absence | Key Considerations |
|---|---|---|---|
| Ethosuximide | T-type calcium channel blocker | First-line for CAE without GTC; ~70% seizure freedom at 12 months | Effective ONLY for absence seizures; does NOT protect against GTC; GI side effects (nausea, vomiting); rare idiosyncratic reactions (SJS, blood dyscrasias) |
| Valproate | Multiple (GABA, Na+, Ca2+ channels) | First-line when GTC seizures coexist; ~70% seizure freedom at 12 months | Broad-spectrum; effective against absence AND GTC; weight gain, tremor, hepatotoxicity, teratogenicity, polycystic ovary syndrome; avoid in women of childbearing potential if possible |
| Lamotrigine | Na+ channel blocker, glutamate modulation | Less effective than ethosuximide or valproate for absence control (~50% at 12 months); better for GTC prevention | Better tolerated; slow titration required (risk of SJS); may worsen myoclonus in some patients; useful add-on or alternative for women |
SANAD Trial Key Findings
- SANAD I (2007): For generalized and unclassified epilepsies, valproate was superior to lamotrigine for seizure control and superior to topiramate for tolerability; valproate was recommended as first-line for newly diagnosed generalized epilepsy
- SANAD II (2021): For childhood absence epilepsy specifically, ethosuximide and valproate were both significantly more effective than lamotrigine; ethosuximide was better tolerated than valproate (fewer behavioral and weight effects); ethosuximide is recommended as first-line for CAE without GTC
- Attentional effects: Children on ethosuximide had better attentional performance than those on valproate, an important consideration for school-age children
Treatment of JAE
Because GTC seizures are common in JAE (~80%), valproate is often preferred as first-line therapy due to its broad-spectrum efficacy against both absence and GTC seizures. In women of childbearing potential, levetiracetam or lamotrigine (with appropriate counseling about lower absence efficacy) may be considered as alternatives. The combination of valproate and lamotrigine can be synergistic for absence seizure control but requires careful titration due to pharmacokinetic interactions (valproate inhibits lamotrigine metabolism, doubling its half-life and increasing the risk of rash).
Treatment Duration and Withdrawal
For CAE, medication withdrawal may be considered after 2 years of seizure freedom, typically in late childhood or early adolescence. EEG normalization (absence of generalized spike-and-wave discharges, including during hyperventilation) supports a higher likelihood of successful withdrawal. Approximately 60–70% of children with CAE achieve permanent remission. For JAE, treatment is generally lifelong, as seizure relapse rates upon medication withdrawal are high (>80%), particularly for GTC seizures.
Medications That Worsen Absence Seizures
- Carbamazepine and oxcarbazepine: Sodium channel blockers that can paradoxically increase absence seizure frequency and may trigger absence status epilepticus
- Phenytoin: Can exacerbate absence seizures
- Vigabatrin: May worsen generalized epilepsy syndromes, including absence seizures
- Tiagabine: Has been associated with increased absence seizure frequency
- Gabapentin and pregabalin: May worsen myoclonic and absence seizures in genetic generalized epilepsy
- Clinical implication: Accurate classification of the epilepsy syndrome BEFORE initiating treatment is critical; misclassifying absence seizures as focal impaired awareness seizures leads to inappropriate use of sodium channel blockers with paradoxical seizure worsening
Absence Status Epilepticus
Absence status epilepticus (also termed spike-wave stupor or petit mal status) is a prolonged state of impaired awareness with continuous or near-continuous generalized spike-and-wave discharges on EEG. It may present as prolonged confusion, decreased responsiveness, or subtle behavioral changes that are difficult to distinguish from nonconvulsive status epilepticus of other causes. Key features:
- May last hours to days if unrecognized
- Can be precipitated by medication withdrawal (particularly benzodiazepines or valproate), intercurrent illness, sleep deprivation, or paradoxically by sodium channel blockers
- EEG shows continuous or near-continuous generalized spike-and-wave activity, typically at 2.5–3.5 Hz
- Treatment: IV benzodiazepines (lorazepam or diazepam) are rapidly effective; oral valproate or ethosuximide for prevention of recurrence
- Prognosis is generally favorable with appropriate treatment; absence status epilepticus does not typically cause permanent neuronal injury
Special Considerations
Genetic Generalized Epilepsy Spectrum
CAE and JAE exist within the broader spectrum of genetic (idiopathic) generalized epilepsies. The ILAE 2022 classification defines four idiopathic generalized epilepsy syndromes: childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone. Understanding the relationships and overlap between these syndromes is essential for accurate diagnosis and treatment:
| Feature | CAE | JAE | JME | Epilepsy With GTCS Alone |
|---|---|---|---|---|
| Typical onset age | 4–10 years | 9–13 years | 10–24 years | 10–25 years |
| Predominant seizure | Typical absences (very frequent) | Typical absences (less frequent) | Myoclonic jerks (especially on awakening) | Generalized tonic-clonic seizures |
| GTC seizures | 15–30% | ~80% | ~90% | 100% (defining feature) |
| Myoclonic jerks | Absent | ~15–25% | Present (defining feature) | Absent |
| Interictal EEG | 2.5–4 Hz spike-wave | 3–5.5 Hz spike-wave | 3–5.5 Hz spike/polyspike-wave | 3–5.5 Hz spike/polyspike-wave |
| Photosensitivity | ~10% | ~15–25% | ~30–90% | Variable |
| Self-limited | Yes (60–70%) | No | No | No |
| First-line ASM | Ethosuximide (if no GTC) | Valproate | Valproate; levetiracetam | Valproate; levetiracetam |
Epilepsy With Myoclonic Absences
Epilepsy with myoclonic absences is a distinct childhood-onset epilepsy syndrome that should be differentiated from CAE:
- Onset between 1 and 12 years (peak 7 years); males are more commonly affected
- Absence seizures are accompanied by prominent rhythmic myoclonic jerks of the shoulders and arms, often with a tonic abduction component—the myoclonic component is bilateral, symmetric, and time-locked to each spike-wave complex
- EEG shows generalized 3 Hz spike-and-wave discharges, but the clinical accompaniment of rhythmic myoclonus differentiates it from typical absences
- Intellectual disability is present in approximately 50% of patients; prognosis is worse than CAE
- Drug-resistant in approximately 50%; valproate and ethosuximide are first-line, but many patients require combination therapy
Epilepsy With Eyelid Myoclonia (Jeavons Syndrome)
Eyelid myoclonia with or without absences is another distinct entity within the generalized epilepsy spectrum:
- Characterized by rapid (3.5–6 Hz) eyelid myoclonia (blinking and upward eye deviation) occurring at eye closure; may be accompanied by brief absence seizures
- Marked photosensitivity; seizures are often provoked by eye closure and photic stimulation
- EEG shows generalized polyspike-and-wave discharges with eye closure and during photic stimulation
- Onset in childhood; typically not self-limited; lifelong photosensitivity management is needed
- May be confused with CAE, but the prominent eyelid myoclonia and photosensitivity are distinguishing features
Women of Childbearing Potential
Valproate and Reproductive-Age Women
- Valproate is a highly effective drug for absence and generalized epilepsy but carries the highest teratogenic risk of all commonly used ASMs: 9–11% rate of major congenital malformations and dose-dependent neurodevelopmental effects (IQ reduction of 7–10 points, increased risk of autism)
- FDA pregnancy category X; contraindicated for migraine and bipolar disorder in women of childbearing potential; requires documented pregnancy prevention counseling for epilepsy use
- For women with JAE or CAE with persistent GTC risk, alternatives include lamotrigine (less effective for absences but safer in pregnancy), levetiracetam (broad-spectrum, pregnancy data accumulating), or combination approaches
- Preconception planning with a neurologist experienced in epilepsy and pregnancy is essential; folic acid supplementation (0.4–4 mg/day depending on risk) should be started before conception
- The SANAD II and MONEAD data inform these discussions; shared decision-making with the patient is critical
Prognosis and Long-Term Outcomes
| Outcome Measure | CAE | JAE |
|---|---|---|
| Seizure freedom rate | 60–70% achieve remission by adolescence | <20% achieve remission off medication |
| Evolution to other epilepsy | 15–30% develop GTC in adolescence; some evolve to JME | May overlap with JME; GTC remain the primary concern |
| Cognitive outcomes | Generally normal; subtle attentional difficulties during active seizures; academic performance normalizes with seizure control | Normal intelligence; academic impact related to seizure control |
| Psychosocial outcomes | Good; quality of life improves with remission | Adequate with seizure control; challenges related to lifelong medication |
| Predictors of remission (CAE) | Younger onset (5–7 years), early response to treatment, absence of GTC, normal EEG at follow-up, absence of photosensitivity | |
| Predictors of non-remission (CAE) | Onset >8 years, development of GTC, persistence of EEG discharges on hyperventilation, poor initial drug response | |
References
- Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1475–1499.
- Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1398–1442.
- Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 2013;54(1):141–155.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566):1016–1026.
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021;397(10282):1375–1386.
- Callenbach PM, Bouma PA, Geerts AT, et al. Long-term outcome of childhood absence epilepsy: Dutch study of epilepsy in childhood. Epilepsy Res 2009;83(2–3):249–256.
- Trinka E, Baumgartner S, Unterberger I, et al. Long-term prognosis for childhood and juvenile absence epilepsy. J Neurol 2004;251(10):1235–1241.
- Mullen SA, Berkovic SF, Lowenstein DH, et al. Genetic generalized epilepsies. Epilepsia 2018;59(6):1148–1153.
- Berg AT, Shinnar S, Levy SR, et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia 2001;42(12):1553–1562.
- Covanis A. Absence epilepsies. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 6th ed. John Libbey Eurotext; 2019:315–342.
- Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006;129(Pt 5):1281–1292.